Previous 10 | Next 10 |
GRX’s total return has been negative, and yield has been quite average over the short term. GRX failed to record double digit average total return over the medium and long term. GRX has a quite high expense ratio and doesn’t have significant investments in any one st...
THW is a rare healthcare fund that performed well in April 2022 as well as in past 3 months and 3 years. THW is relatively better protected from market risk due to exposure in global equity markets. THW’s stock selection is impressive, and top investments generated high pos...
With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns. Retirees and conservative investors need income, growth to meet inflation, and most importantly, conservation of capital ...
HQL pays regular quarterly dividends with a close to double digit yield, and despite poor price growth over medium and long run, HQL’s total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movemen...
Tekla Capital's managed funds have announced one-year extension of their stock buyback program to now expire on June. 14, 2023. It comes from Tekla Healthcare Opportunities Fund (THQ +0.6%), Tekla Healthcare Investors (HQH +1.3%), Tekla World Healthcare Fund (THW +0.7%), and Tekla Life Scienc...
Tekla Life Sciences (NYSE:HQL) declares $0.39/share quarterly dividend, -7.1% decrease from prior dividend of $0.42. Forward yield 8.86% Payable March 31; for shareholders of record Feb. 25; ex-div Feb. 24. See HQL Dividend Scorecard, Yield Chart, & Dividend Growth. For further details ...
The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...
HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. For further details see: Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
As dividend investors—and closed-end fund (CEF) investors, specifically—we know to stay the course when market corrections hit: we don’t want to sell and cut off our precious payouts! That’s the opposite of the fanboys and girls who dabble in crypto, prof...
These days, everyone’s in a tizzy about rising interest rates. But what if I told you that this panic is overblown—and it’s setting us up for some very nice windows to buy some top-quality high-yield funds throwing off payouts of 7% and up? Why do I think it...
News, Short Squeeze, Breakout and More Instantly...
TeklaLife Sciences Investors Company Name:
HQL Stock Symbol:
NYSE Market:
TeklaLife Sciences Investors Website:
2024-08-01 06:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 05:00:37 ET Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts. I was reminded of this recently by a ...
PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024. As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% o...